The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy. This long term follow up study is observational and no treatment is provided for HCV infection.

Inclusion Criteria:

• Patients with chronic hepatitis C treated with interferon-based therapy or direct-acting agents (DAAs)-based regimen;
• Provide written, informed consent;
• Be willing and able to comply with the visit schedule and protocol-mandated procedures.

Exclusion Criteria:

• Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up time frame;
• History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol.
• Inability to provide written informed consent.

Subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy.